ResMed Inc. (NYSE:RMD) insider Richard Mchale sold 1,800 shares of the stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $111.56, for a total transaction of $200,808.00. Following the transaction, the insider now owns 23,507 shares of the company’s stock, valued at approximately $2,622,440.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NYSE:RMD opened at $112.13 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.58 and a quick ratio of 1.91. The stock has a market cap of $15.98 billion, a price-to-earnings ratio of 31.76, a price-to-earnings-growth ratio of 2.86 and a beta of 1.01. ResMed Inc. has a twelve month low of $83.60 and a twelve month high of $116.64.
ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 25th. The medical equipment provider reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.01. The firm had revenue of $588.28 million during the quarter, compared to analyst estimates of $576.66 million. ResMed had a net margin of 13.94% and a return on equity of 26.29%. Analysts predict that ResMed Inc. will post 3.7 EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of ResMed by 0.5% in the third quarter. Vanguard Group Inc. now owns 14,567,805 shares of the medical equipment provider’s stock worth $1,680,251,000 after buying an additional 69,129 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of ResMed by 2.1% in the third quarter. BlackRock Inc. now owns 11,180,412 shares of the medical equipment provider’s stock worth $1,289,550,000 after buying an additional 226,612 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in shares of ResMed by 0.3% in the third quarter. Baillie Gifford & Co. now owns 4,841,478 shares of the medical equipment provider’s stock worth $558,416,000 after buying an additional 14,627 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of ResMed by 0.7% in the third quarter. Bank of New York Mellon Corp now owns 1,632,771 shares of the medical equipment provider’s stock worth $188,324,000 after buying an additional 11,927 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of ResMed by 323.1% in the third quarter. Deutsche Bank AG now owns 1,367,475 shares of the medical equipment provider’s stock worth $157,721,000 after buying an additional 1,044,295 shares in the last quarter. 65.02% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have weighed in on RMD. BMO Capital Markets increased their target price on shares of ResMed from $107.00 to $109.00 and gave the stock a “market perform” rating in a research report on Friday, October 26th. Credit Suisse Group upgraded shares of ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $114.50.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/12/06/insider-selling-resmed-inc-rmd-insider-sells-200808-00-in-stock.html.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Further Reading: How a Put Option Works
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.